Free Trial

10,100 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Caas Capital Management LP

Hims & Hers Health logo with Medical background

Caas Capital Management LP bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,100 shares of the company's stock, valued at approximately $298,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Blume Capital Management Inc. boosted its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. Summit Securities Group LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at about $38,000. UMB Bank n.a. boosted its holdings in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after acquiring an additional 961 shares during the last quarter. Finally, Tsfg LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $46,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 17,102 shares of Hims & Hers Health stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the sale, the insider directly owned 278,654 shares in the company, valued at $16,649,576.50. This trade represents a 5.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 8,485 shares of Hims & Hers Health stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $506,978.75. Following the sale, the insider owned 712 shares in the company, valued at $42,542. This represents a 92.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 670,250 shares of company stock worth $34,487,591. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Down 4.7%

HIMS stock traded down $2.36 during midday trading on Friday, hitting $47.91. The company's stock had a trading volume of 18,925,676 shares, compared to its average volume of 23,837,558. The firm has a market capitalization of $10.72 billion, a P/E ratio of 69.44, a PEG ratio of 1.85 and a beta of 2.02. The firm has a 50-day simple moving average of $53.54 and a 200-day simple moving average of $40.82. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company's revenue for the quarter was up 110.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.05 EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HIMS. Morgan Stanley restated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Bank of America upped their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Piper Sandler restated a "neutral" rating and issued a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $39.58.

Check Out Our Latest Research Report on Hims & Hers Health

About Hims & Hers Health

(Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

See Also

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Should You Invest $1,000 in Hims & Hers Health Right Now?

Before you consider Hims & Hers Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.

While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines